Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...

AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 ...

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average price of $12.95 ...

After hours: February 7 at 7:23:36 PM EST ...